Use of anti-cd100 antibodies

Abstract

The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.

1 . A method for treating a neuroinflammatory disorder in a subject, said method comprising administering an effective amount of an anti-CD100 antibody or an antigen-binding fragment thereof to said subject, wherein said anti-CD100 antibody or an antigen-binding fragment thereof blocks the interaction of soluble CD100 with plexin B1 receptor. 
     
     
         2 . The method of  claim 1 , wherein said neuroinflammatory disorder is a central nervous system (CNS) inflammatory disorder. 
     
     
         3 . The method of  claim 1 , wherein said neuroinflammatory disorder is a peripheral nervous system (PNS) inflammatory disorder. 
     
     
         4 . The method of  claim 1 , wherein said subject has a high level of soluble CD100 in a biological sample taken from said subject when compared to a control subject. 
     
     
         5 . The method of  claim 4 , wherein said biological sample is cerebral spinal fluid (CSF) or blood. 
     
     
         6 . The method of  claim 1 , wherein said neuroinflammatory disorder is a myelin disorder or a disease that affects oligodendrocytes 
     
     
         7 . The method of  claim 1 , wherein said neuroinflammatory disorder is a disease that affects myelinating peripheral cells. 
     
     
         8 . The method of  claim 1 , wherein said neuroinflammatory disorder is selected from the group consisting of an oligodendroglioma, leucodystrophy, Guillain-Barrésyndrome, Alexander disease, Canavan disease, Krabbe disease, Pelizaeus-Merzbacher disease, Zellweger disease, Refsum disease, CACH disease, X-linked adrenoleucodystrophy, adrenoleucodystrophy, adrenomyeloneuropathy, leucodystrophies of undetermined origin, HTLV-1 associated myelopathy, multiple sclerosis, and polyradiculoneuritis. 
     
     
         9 . The method of  claim 8 , wherein said neuroinflammatory disorder is HTLV-1 associated myelopathy. 
     
     
         10 . The method of  claim 8 , wherein said neuroinflammatory disorder is polyradiculoneuritis. 
     
     
         11 . The method of  claim 8 , wherein said neuroinflammatory disorder is multiple sclerosis. 
     
     
         12 . The method of  claim 1 , wherein said neuroinflammatory disorder is a post-trauma myelin disorder of the central or peripheral nervous system. 
     
     
         13 . The method of  claim 1 , wherein said anti-CD100 antibody is a chimeric, humanized, or human antibody. 
     
     
         14 . A method for protecting neural progenitor cells or oligodendrocytes from cell death, said method comprising administering to a subject an effective amount of an anti-CD100 antibody or an antigen-binding fragment thereof, and wherein said anti-CD100 antibody or an antigen-binding fragment thereof blocks the interaction of soluble CD100 with plexin B1 receptor. 
     
     
         15 . The method of  claim 14 , wherein said subject has a high level of soluble CD100 in a biological sample taken from said subject in comparison to a control subject. 
     
     
         16 . The method of  claim 15 , wherein said biological sample is cerebral spinal fluid (CSF) or blood. 
     
     
         17 . The method of  claim 14 , wherein said anti-CD100 antibody is a chimeric, humanized, or human antibody.